Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (341-350 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Pageof 48

Showing results (341-350 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
British Journal of Haematology|November 20, 2020
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myelomaJithma P Abeykoon, David L Murray, Isaiah Murray, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Pageof 48